Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects

Next Previous
Trial Profile

A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selumetinib (Primary) ; Paracetamol
  • Indications Biliary cancer; Colorectal cancer; Gastric cancer; Glioma; Histiocytosis; Kaposi's sarcoma; Myelodysplastic syndromes; Myelofibrosis; Neurofibromatosis 1; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 08 Apr 2022 Results assessing the pharmacokinetic properties and palatability of a new granule formulation of selumetinib published in the Clinical Therapeutics
    • 07 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2018 Planned End Date changed from 2 Nov 2018 to 29 Oct 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top